Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. This evidence concerns the gene RUNX3 and pancreatic ductal adenocarcinoma.